Laboratory Corp. of America Holdings Could Decline a Lot According to The Today’s Call Option Activity

 Laboratory Corp. of America Holdings Could Decline a Lot According to The Today's Call Option Activity

In today’s session Laboratory Corp. of America Holdings (LH) recorded an unusually high (197) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious LH decrease. With 197 contracts traded and 3574 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: LH161216P00120000 closed last at: $0.6 or 29.4% down. About 50,801 shares traded hands. Laboratory Corp. of America Holdings (NYSE:LH) has risen 3.48% since April 22, 2016 and is uptrending. It has underperformed by 1.93% the S&P500.

Analysts await Laboratory Corp. of America Holdings (NYSE:LH) to report earnings on February, 16. They expect $2.19 earnings per share, up 10.61% or $0.21 from last year’s $1.98 per share. LH’s profit will be $227.87M for 14.46 P/E if the $2.19 EPS becomes a reality. After $2.25 actual earnings per share reported by Laboratory Corp. of America Holdings for the previous quarter, Wall Street now forecasts -2.67% negative EPS growth.

Laboratory Corp. of America Holdings (NYSE:LH) Ratings Coverage

Out of 10 analysts covering Laboratory Corp (NYSE:LH), 4 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 40% are positive. Laboratory Corp has been the topic of 17 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Citigroup initiated the stock with “Neutral” rating in Friday, September 9 report. Barclays Capital maintained Laboratory Corp. of America Holdings (NYSE:LH) rating on Tuesday, April 26. Barclays Capital has “Overweight” rating and $155 price target. UBS maintained Laboratory Corp. of America Holdings (NYSE:LH) rating on Tuesday, April 26. UBS has “Neutral” rating and $125 price target. Zacks downgraded the shares of LH in a report on Monday, August 17 to “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $140 target price in Tuesday, April 26 report. The firm has “Overweight” rating by KeyBanc Capital Markets given on Tuesday, August 16. The firm has “Sector Perform” rating given on Friday, February 19 by RBC Capital Markets. On Thursday, September 15 the stock rating was maintained by Mizuho with “Neutral”. The stock of Laboratory Corp. of America Holdings (NYSE:LH) earned “Hold” rating by Jefferies on Tuesday, April 26. The rating was downgraded by Goldman Sachs to “Neutral” on Tuesday, December 8.

According to Zacks Investment Research, “Laboratory Corporation of America Holdings, is one of the largest independent clinical laboratory company’s in the United States. Through a national network of laboratories, the company offers different clinical laboratory tests which are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease.”

Insitutional Activity: The institutional sentiment decreased to 1.01 in 2016 Q2. Its down 0.43, from 1.44 in 2016Q1. The ratio fall, as 32 funds sold all Laboratory Corp. of America Holdings shares owned while 192 reduced positions. 89 funds bought stakes while 233 increased positions. They now own 92.00 million shares or 4.08% less from 95.92 million shares in 2016Q1.
Evercore Wealth Limited Liability accumulated 0.01% or 1,632 shares. Moreover, Westpac Bk has 0% invested in Laboratory Corp. of America Holdings (NYSE:LH) for 5,321 shares. Peak Asset Ltd has 0.13% invested in the company for 2,174 shares. Rockefeller Financial Serv, a New York-based fund reported 134 shares. Duncker Streett & Company has 0.22% invested in the company for 4,703 shares. Taylor Asset Management Inc last reported 32,000 shares in the company. Cibc Asset Mgmt accumulated 0.01% or 14,881 shares. Security Bankshares Of Sioux City Iowa Ia holds 14,171 shares or 2.09% of its portfolio. Gulf Int Commercial Bank (Uk) holds 0.06% or 29,581 shares in its portfolio. Art holds 0.11% of its portfolio in Laboratory Corp. of America Holdings (NYSE:LH) for 16,844 shares. Fiduciary Of The Southwest Tx last reported 2,285 shares in the company. Sumitomo Mitsui Incorporated has invested 0.07% of its portfolio in Laboratory Corp. of America Holdings (NYSE:LH). Keybank National Association Oh has 0% invested in the company for 5,065 shares. Lombard Odier Asset Mgmt (Switzerland) accumulated 0.25% or 14,150 shares. Iberiabank Corporation has 0.09% invested in the company for 1,629 shares.

Insider Transactions: Since June 13, 2016, the stock had 0 insider purchases, and 4 selling transactions for $26.56 million net activity. $164,780 worth of Laboratory Corp. of America Holdings (NYSE:LH) was sold by Uthgenannt Lisa J. 196,400 shares were sold by KING DAVID P, worth $25.14 million. MITTELSTAEDT ROBERT E JR had sold 992 shares worth $139,027. EISENBERG GLENN A sold $1.12 million worth of Laboratory Corp. of America Holdings (NYSE:LH) on Thursday, August 4.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The company has a market cap of $13.18 billion. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. It has a 19.98 P/E ratio. The Firm operates through two divisions: LabCorp Diagnostics and Covance Drug Development (CDD).

LH Company Profile

Laboratory Corporation of America Holdings, incorporated on March 8, 1994, is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Firm operates through two divisions: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Another recent and important Laboratory Corp. of America Holdings (NYSE:LH) news was published by Businesswire.com which published an article titled: “Computerworld Names Covance’s Dimitris Agrafiotis a Premier 100 Technology Leader” on November 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment